THERAPEUTICS
Self-monitoring of blood glucose was not cost-effective in non–insulin-treated type 2 diabetes
| The first 150 words of the full text of this article appear below. |
J Simon
Dr J Simon, University of Oxford, Oxford, UK; judit.simon@dphpc.ox.ac.uk
STUDY DESIGN
cost-effectiveness analysis of a randomised controlled trial with 1-year follow-up (Diabetes Glycaemic Education and Monitoring [DiGEM]).
STUDY QUESTION
48 general practices in the UK.
453 patients {mean age 66 y, 57% men}* who had non–insulin-treated type 2 diabetes with haemoglobin (Hb) A1c concentrations
6.2% and were not self-monitoring glucose. {Exclusion criteria included serious disease}.*
Intensive self-monitoring of blood glucose (SMBG, n = 151), SMBG (n = 150), or usual care (n = 152). The intensive SMBG group was trained to interpret results and adjust diet, physical activity, and drug adherence. The SMBG group contacted their physicians to interpret glucose-meter readings.
Quality-adjusted life-years (QALYs) and healthcare costs. Costs were calculated by multiplying volume of resource use by the UK national level unit cost and expressed in 2005–2006 pounds sterling. Differences in costs between groups were adjusted for variations in cost at 12
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
